928797-50-6

Basic information

• Product Name: Ethyl 3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-difluoro-3-hydroxypropionate
• Synonyms: Ethyl 3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-difluoro-3-hydroxypropionate;2'3'-diacetate;Ethyl 3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-difluoro-3-hydroxypropiote
• CAS NO: 928797-50-6
• Molecular Formula: C₁₀H₁₆F₂O₅
• Molecular Weight: 254
• Mol File: 928797-50-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 338℃
• Flash Point: 159℃
• Appearance: /
• Density: 1.232
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.428
• PKA: 11.95±0.20(Predicted)
• CAS DataBase Reference: Ethyl 3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-difluoro-3-hydroxypropionate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-difluoro-3-hydroxypropionate(928797-50-6)
• EPA Substance Registry System: Ethyl 3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-difluoro-3-hydroxypropionate(928797-50-6)

Safety Data

• Hazardous Substances Data: 928797-50-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H16F2O5/c1-4-15-8(14)10(11,12)7(13)6-5-16-9(2,3)17-6/h6-7,13H,4-5H2,1-3H3/t6-,7-/m1/s1

Upstream product

• 50271-42-6 5,6-O-isopropylidene-D-isoascorbic acid 
• 136136-17-9 O³,O⁴-(1-methylethylidene)-D-erythronic acid 
• 1707-77-3 1,2:5,6-di-O-isopropylidene-D-mannitol 
• 667-27-6 Ethyl bromodifluoroacetate 
• 15186-48-8 2,3-isopropylidene-glyceraldehyde 

Downstream Products

• 1241891-43-9 ethyl 2,2-difluoro-3-(4-biphenylcarbonyloxy)-3-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)propionate 
• 95058-77-8 2-deoxy-2,2-difluoro-1-carbonylribose 
• 873849-99-1 ethyl (R)-2,2-difluoro-3-(4-biphenylcarbonyloxy)-3-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)propionate 
• 122111-01-7 2-deoxy-2,2-difluoro-D-erythro-pentonic acid γ-lactone 3,5-dibenzoate 
• 1173824-58-2 (2R,3R)-2-((benzoyloxy)methyl)-4,4-difluoro-5-hydroxyoxolan-3-yl benzoate 
• 134877-42-2 3,5-di-O-benzoyl-2-deoxy-2,2-difluoro-1-O-methanesulfonyl-D-erythro-pentofuranose 
• 1147119-11-6 (3R,4R)-5-trityloxy-3-benzoyloxy-2,2-difluoro-pentanoic acid γ-lactone 
• 1147119-07-0 (3R,4R)-5-trityloxy-3-hydroxy-2,2-difluoro-pentanoic acid γ-lactone 
• 1147119-15-0 (2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4,4-difluoro-2-(trityloxymethyl)tetrahydrofuran-3-yl Benzoate 
• 1147119-14-9 (2R,3R)-4,4-difluoro-5-iodo-2-(trityloxymethyl)tetrahydrofuran-3-yl benzoate 
• 1147119-13-8 (2R,3R)-4,4-difluoro-5-(methylsulfonyloxy)-2-(trityloxymethyl)tetrahydrofuran-3-yl benzoate 
• 1147119-08-1 C₇H₁₂F₂O₅ 
• 1147119-10-5 (3R,4R)-2,2-Difluoro-3,4,5-trihydroxy-pentanoic acid 
• 166376-97-2 (threo) ethyl-3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-difluoro-3-hydroxy propionate 

Relevant articles and documents

High-selectivity synthesis method for gemcitabine intermediate

The invention discloses a high-selectivity synthesis method for a gemcitabine intermediate. The high-selectivity synthesis method specifically comprises the following process: Step 1, synthesis of T1;Step2, synthesis of T2, to be specific, 550kg of hydrogen peroxide is dropwise added into the T1, and a reaction is controlled to produce the T2; Step3, synthesis of T3, to be specific, sodium acetate trihydrate or sodium carbonate is added into a reaction kettle, the PH value is adjusted with glacial acetic acid, a 10%-15% sodium hypochlorite aqueous solution is dropwise added, and a reaction iscontrolled to produce the T3; Step 4, synthesis of T4; Step 5, synthesis of T5; Step 6, synthesis of T6; Step 7, synthesis of T7; Step 8, synthesis of T8; and Step9, T8 configuration transformation.The high-selectivity synthetic method for the gemcitabine intermediate can reduce the production cost, and meanwhile, can also increase the yield of the gemcitabine intermediate.

1,3-dimethyl-7-substituted quinazoline-2,4-dione fluorine-containing amide compound and synthesizing method and application thereof

The invention discloses a 1,3-dimethyl-7-substituted quinazoline-2,4-dione fluorine-containing amide compound. The 1,3-dimethyl-7-substituted quinazoline-2,4-dione fluorine-containing amide compound is shown as a general formula in the specification, wherein R1 refers to hydrogen or ethyl, and R2 refers to a benzene ring, a benzene ring derivative, a heterocyclic ring or fatty hydrocarbon. Biological activity test experiments prove that the 1,3-dimethyl-7-substituted quinazoline-2,4-dione fluorine-containing amide compound shows good inhibiting activity for Monilia albicans, Cryptococcus neoformans and Aspergillus fumigates, is remarkable in chitin synthetase inhibiting activity and good in antibacterial effect and can be used for preparing drugs for resisting pathogenic microorganisms.

Stereospecific synthesis of 2-deoxy-2,2-difluororibonolactone and its use in the preparation of 2'-deoxy-2',2'-difluoro-β-D-ribofuranosyl pyrimidine nucleosides: The key role of selective crystallization

A stereospecific synthesis of 2'-deoxy-2',2'-difluorocytidine (gemcitabine), a potential anticancer agent, is described. The stereoselectivity was accomplished via two diastereoselective crystallizations, i.e. the crystallization of the key intermediate, difluororibonolactone 2a, and the crystallization of the hydrochloride salt of gemcitabine 16b from the anomeric mixture. Because of the availability of 2a in large quantities, other 2'-deoxy-2',2'-difluoropyrimidine nucleosides such as 2'-deoxy-2',2'-difluorouridine (19) were synthesized for structure-activity relationship studies.